{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:57:24Z","timestamp":1777348644631,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","award":["2I01CX000920-04"],"award-info":[{"award-number":["2I01CX000920-04"]}],"id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgar.2020.12.017","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T02:42:20Z","timestamp":1610937740000},"page":"190-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Activity of meropenem\/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region"],"prefix":"10.1016","volume":"24","author":[{"given":"Brian D.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Thuras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2020.12.017_bib0005","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3201\/eid2011.141388","article-title":"Global incidence of carbapenemase-producing Escherichia coli ST131","volume":"20","author":"Peirano","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jgar.2020.12.017_bib0010","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/jac\/dkr226","article-title":"Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases","volume":"66","author":"Mushtaq","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.12.017_bib0015","first-page":"1057","article-title":"Occurrence of OXA-48 carbapenemase and other \u03b2-lactamase genes in ESBL-producing multidrug resistant Escherichia coli from dogs and cats in the United States, 2009\u20132013","volume":"7","author":"Liu","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2020.12.017_bib0020","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1128\/AAC.00912-13","article-title":"Emergence of Escherichia coli sequence type 131 isolates producing KPC-2 carbapenemase in China","volume":"58","author":"Cai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.12.017_bib0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13756-018-0346-9","article-title":"A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States","volume":"7","author":"Livorsi","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2020.12.017_bib0030","article-title":"Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party","volume":"73","author":"Hawkey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.12.017_bib0035","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.jgar.2020.12.017_bib0040","doi-asserted-by":"crossref","first-page":"e00567","DOI":"10.1128\/AAC.00567-17","article-title":"Meropenem\u2013vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.12.017_bib0045","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijantimicag.2018.02.021","article-title":"In vitro activity of meropenem\/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem\/vaborbactam surveillance programme","volume":"52","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2020.12.017_bib0050","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1128\/JCM.00984-13","article-title":"Predictive diagnostics for Escherichia coli infections based on the clonal association of antimicrobial resistance and clinical outcome","volume":"51","author":"Tchesnokova","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2020.12.017_bib0055","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw002","article-title":"A novel 7-single nucleotide polymorphism-based clonotyping test allows rapid prediction of antimicrobial susceptibility of extraintestinal Escherichia coli directly from urine specimens","volume":"3","author":"Tchesnokova","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2020.12.017_bib0060","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00732-17","article-title":"Epidemic emergence in the United States of Escherichia coli sequence type 131-H30 (ST131-H30), 2000\u20132009","volume":"61","author":"Johnson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.12.017_bib0065","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1128\/AAC.00673-15","article-title":"Intensity and mechanisms of fluoroquinolone resistance within the H30 and H30Rx subclones of Escherichia coli sequence type 131 vs. other fluoroquinolone-resistant E. coli","volume":"59","author":"Johnson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.12.017_bib0070","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1128\/AAC.01687-15","article-title":"Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131","volume":"59","author":"Johnson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.12.017_bib0075","series-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2020"},{"key":"10.1016\/j.jgar.2020.12.017_bib0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/1758-2229.12019","article-title":"The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups","volume":"5","author":"Clermont","year":"2012","journal-title":"Environ Microbiol Rep"},{"key":"10.1016\/j.jgar.2020.12.017_bib0085","doi-asserted-by":"crossref","first-page":"e01664","DOI":"10.1128\/JCM.01664-18","article-title":"Rapid emergence, subsidence, and molecular detection of Escherichia coli sequence type 1193-fimH64 (ST1193-H64), a new disseminated multidrug-resistant commensal and extraintestinal pathogen","volume":"57","author":"Johnson","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2020.12.017_bib0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mimet.2014.03.008","article-title":"Development of an allele-specific PCR for Escherichia coli B2 sub-typing, a rapid and easy to perform substitute of multilocus sequence typing","volume":"101","author":"Clermont","year":"2014","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.jgar.2020.12.017_bib0095","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx089","article-title":"The pandemic H30 subclone of sequence type 131 (ST131) is the leading cause of multidrug-resistant Escherichia coli infections in the United States (2011\u20132012)","volume":"4","author":"Johnson","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2020.12.017_bib0100","first-page":"161","article-title":"Diversity of CTX-M \u03b2-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals","volume":"209","author":"Saladin","year":"2002","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.jgar.2020.12.017_bib0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","article-title":"Multiplex PCR for detection of acquired carbapenemase genes","volume":"70","author":"Poirel","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2020.12.017_bib0110","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1128\/JCM.40.6.2153-2162.2002","article-title":"Detection of plasmid-mediated AmpC \u03b2-lactamase genes in clinical isolates by using multiplex PCR","volume":"40","author":"Perez-Perez","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2020.12.017_bib0115","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw129","article-title":"Household clustering of Escherichia coli sequence type 131 clinical and fecal isolates according to whole genome sequence analysis","volume":"3","author":"Johnson","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2020.12.017_bib0120","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.2832","article-title":"Chi-squared and Fisher\u2013Irwin tests of two-by-two tables with small sample recommendations","volume":"26","author":"Campbell","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.jgar.2020.12.017_bib0125","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa495","article-title":"Bacterial\u2019 virulence\u2019 traits and host demographics predict Escherichia coli colonization behaviors within households","volume":"7","author":"Fox","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2020.12.017_bib0130","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx063","article-title":"Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials","volume":"4","author":"Alexander","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2020.12.017_bib0135","first-page":"e00377","article-title":"The epidemic of ESBL-producing Escherichia coli ST131 is driven by a single highly virulent subclone, H30-Rx","volume":"6","author":"Price","year":"2013","journal-title":"mBio"},{"key":"10.1016\/j.jgar.2020.12.017_bib0140","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.02304-15","article-title":"What is the appropriate meropenem MIC for screening of carbapenemase-producing Enterobacteriaceae in low-prevalence settings?","volume":"60","author":"Fattouh","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.12.017_bib0145","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:54:54Z","timestamp":1761990894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":29,"alternative-id":["S2213716521000023"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.12.017","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of meropenem\/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}